文献速递骨肌US

钙羟基磷灰石沉积病的常见治疗策略:成本效果分析

Common treatment strategies for calcium hydroxyapatite deposition disease: a cost-effectiveness analysis.
PubMed 文献 · Skeletal Radiol · 2023-08-14

研究基于美国医疗体系视角,构建1年时间跨度的决策分析模型,模拟52岁女性肩袖钙羟基磷灰石沉积病保守治疗失败后的治疗策略。超声引导下针吸灌洗术(UGB)为最优策略(ICER $33,992.99),手术和低能量体外冲击波治疗为劣势策略。

要点

  • UGB的ICER为$33,992.99,低于$100,000的支付意愿阈值,为成本效果最优策略。
  • 手术和低能量体外冲击波治疗均被优势策略排除(dominated)。

核心结论

  • UGB似乎是钙羟基磷灰石沉积病患者最具成本效果的策略。
  • 手术和低能量体外冲击波治疗成本效果最差。
  • 在合适的临床情况下,保守治疗可考虑作为合理的替代治疗策略。

研究设计与样本

  • 研究类型为成本效果分析,采用1年时间跨度的决策分析模型,从美国医疗体系视角构建。
  • 模拟对象为52岁女性肩袖钙羟基磷灰石沉积病且保守治疗失败的患者。
  • 评估策略包括保守治疗、超声引导下针吸灌洗术(UGB)、高能量和低能量体外冲击波治疗(ECSW)以及手术。
  • 主要效果指标为质量调整生命年(QALY),成本以2022年美元估算,支付意愿阈值为$100,000。

诊断标准与关键数值

  • 基础病例中UGB为优选策略:0.9725 QALY,总成本$2199.35,净货币效益$95,048.45,ICER $33,992.99。
  • 保守治疗为合理替代方案:0.9670 QALY,净货币效益$94,688.83。
  • 手术(0.9532 QALY,净货币效益$92,092.46)和低能量ECSW(0.9287 QALY,净货币效益$87,881.20)均为劣势策略。
  • 敏感性分析显示高能量ECSW成本低于$2905.66时成为优选策略,保守治疗成本低于$990.34时成为优选策略。

临床应用与阅片要点

  • 概率敏感性分析支持基础病例结果:UGB在43%的模拟中被优选,高能量ECSW为36%,保守治疗为20%,低能量ECSW和手术均低于1%。
  • 作者认为UGB似乎是钙羟基磷灰石沉积病患者最具成本效果的策略。
  • 作者认为在合适的临床情况下,保守治疗可考虑作为合理的替代治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To determine the cost-effectiveness of rotator cuff hydroxyapatite deposition disease (HADD) treatments.

METHOD: A 1-year time horizon decision analytic model was created from the US healthcare system perspective for a 52-year-old female with shoulder HADD failing conservative management. The model evaluated the incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB) of standard strategies, including conservative management, ultrasound-guided barbotage (UGB), high- and low-energy extracorporeal shock wave therapy (ECSW), and surgery. The primary effectiveness outcome was quality-adjusted life years (QALY). Costs were estimated in 2022 US dollars. The willingness-to-pay (WTP) threshold was $100,000.

RESULTS: For the base case, UGB was the preferred strategy (0.9725 QALY, total cost, $2199.35, NMB, $95,048.45, and ICER, $33,992.99), with conservative management (0.9670 QALY, NMB $94,688.83) a reasonable alternative. High-energy ECSW (0.9837 QALY, NMB $94,805.72), though most effective, had an ICER of $121, 558.90, surpassing the WTP threshold. Surgery (0.9532 QALY, NMB $92,092.46) and low-energy ECSW (0.9287 QALY, NMB $87,881.20) were each dominated. Sensitivity analysis demonstrated that high-energy ECSW would become the favored strategy when its cost was < $2905.66, and conservative management was favored when the cost was < $990.34. Probabilistic sensitivity analysis supported the base case results, with UGB preferred in 43% of simulations, high-energy ECSW in 36%, conservative management in 20%, and low-energy ECSW and surgery in < 1%.

CONCLUSION: UGB appears to be the most cost-effective strategy for patients with HADD, while surgery and low-energy ECSW are the least cost-effective. Conservative management may be considered a reasonable alternative treatment strategy in the appropriate clinical setting.

来源:Skeletal Radiol,查看原文。版权归原作者所有。

引用

  1. Alaia EF, Subhas N, Da Silva Cardoso M, et al. Common treatment strategies for calcium hydroxyapatite deposition disease: a cost-effectiveness analysis. Skeletal Radiol. 2023. PMID: 37580537. doi:10.1007/s00256-023-04424-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。